title: Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
abstract: BACKGROUND
  The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered olaparib (AZD2281) in combination with topotecan in patients with advanced solid tumors.
  
  
  METHODS
  Patients aged ≥ 18 years with histologically or cytologically diagnosed advanced solid tumors for whom no suitable effective therapy exists were included. Patients in four cohorts received topotecan (0.5 mg/m(2)/day × 3 days or 1.0 mg/m(2)/day × 3 days) intravenously in combination with oral olaparib 50, 100 or 200 mg bid for six cycles. The primary objectives were to determine the safety and tolerability and to establish the MTD of olaparib in combination with topotecan.
  
  
  RESULTS
  Twenty-one patients were enrolled and 19 received treatment. Dose-limiting toxicities were neutropenia and thrombocytopenia. The MTD was established as topotecan 1.0 mg/m(2)/day × 3 days plus olaparib 100 mg bid. The most common adverse events (AEs) included fatigue and gastrointestinal events. There was an olaparib and topotecan dose-related increase in neutropenia which was dose limiting.
  
  
  CONCLUSIONS
  Further development of olaparib and topotecan in combination was not explored due to dose-limiting hematological AEs and the resulting sub-therapeutic MTD.
authors: St George's Hospital, Blackshaw Rd, London, UK.
authors: Jens
authors: J
authors: Samol
authors: Malcolm
authors: M
authors: Ranson
authors: Edwina
authors: E
authors: Scott
authors: Euan
authors: E
authors: Macpherson
authors: James
authors: J
authors: Carmichael
authors: Anne
authors: A
authors: Thomas
authors: James
authors: J
authors: Cassidy
references: Cancer Res. 2010 Feb 15;70(4):1700-10
references: 20145144
references: Mol Pharmacol. 2002 Sep;62(3):439-45
references: 12181418
references: J Clin Oncol. 1997 Jun;15(6):2183-93
references: 9196130
references: Lancet. 2010 Jul 24;376(9737):235-44
references: 20609467
references: Clin Cancer Res. 2008 Jun 15;14(12):3916-25
references: 18559613
references: N Engl J Med. 2009 Jul 9;361(2):123-34
references: 19553641
references: Cell Cycle. 2007 Nov 15;6(22):2782-7
references: 17998803
references: Pharmacol Rev. 2002 Sep;54(3):375-429
references: 12223530
references: J Clin Oncol. 1999 Feb;17(2):658-67
references: 10080612
references: Nature. 2008 Feb 28;451(7182):1111-5
references: 18264088
references: J Med Chem. 2008 Oct 23;51(20):6581-91
references: 18800822
references: Oncology. 1999;56(1):1-12
references: 9885371
references: Biochem Pharmacol. 2008 Oct 1;76(7):850-61
references: 18703021
references: J Clin Oncol. 2010 May 20;28(15):2512-9
references: 20406929
references: Lancet. 2010 Jul 24;376(9737):245-51
references: 20609468
references: N Engl J Med. 2011 Jan 20;364(3):205-14
references: 21208101
references: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
references: 18971340
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: Nature. 2001 May 17;411(6835):366-74
references: 11357144